{"id":"NCT02592421","sponsor":"The University of Texas Health Science Center at San Antonio","briefTitle":"SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2","officialTitle":"Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-23","primaryCompletion":"2018-10-01","completion":"2019-10-31","firstPosted":"2015-10-30","resultsPosted":"2019-12-18","lastUpdate":"2020-09-17"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Type II Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Farxiga"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.","primaryOutcome":{"measure":"Change in Plasma Glucose Concentration","timeFrame":"Baseline to 240-300 minutes","effectByArm":[{"arm":"Dapagliflozin","deltaMin":-29.7,"sd":3},{"arm":"Placebo","deltaMin":-17.2,"sd":2.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["31915153"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Nausea"]}}